Sawmiller D R, Fenton R A, Dobson J G
Department of Physiology, University of Massachusetts Medical School, Worcester 01655, USA.
Am J Physiol. 1996 Jul;271(1 Pt 2):H235-43. doi: 10.1152/ajpheart.1996.271.1.H235.
Myocardial contractile responsiveness to beta-adrenoceptor stimulation is known to be reduced with maturation or aging. The present study was undertaken to determine the role of antiadrenergic A1 and stimulatory A2 adenosine receptors in the modulation of beta-adrenergic-elicited contractile performance of the heart at juvenile (approximately 25 days) and adult (approximately 79 days) stages of maturation. Isoproterenol, a beta-adrenergic agonist, at 10(-7) M produced a greater maximal increase in contractility, assessed as the maximal rate of left ventricular pressure development (+dP/dtmax), in immature than in mature hearts (104 and 80%, respectively), but produced a greater increase in venous adenosine concentration in the mature than in the immature hearts (738 and 277 nM, respectively). Isoproterenol at 10(-9) to 10(-8) M produced similar increases in contractility in the absence or presence of the A1 adenosine receptor antagonist xanthine amine congener (XAC; 0.5 microM) for both immature and mature hearts. In addition, XAC did not alter the isoproterenol-elicited contractile response in the immature heart during hypoperfusion induced by 50% reduction of coronary flow. However, in the mature heart, 10(-8) M isoproterenol elicited a significantly greater increase in +dP/dtmax during hypoperfusion in the presence (79%) vs. the absence (60%) of XAC. In both immature and mature hearts, hypoperfusion enhanced isoproterenol-elicited venous adenosine concentration by similar magnitudes of 76 and 72%, respectively. In further studies, the A2 adenosine receptor antagonist 9-chloro-2-(2-furyl)[1,2,4]-triazolo[1,5-c]quinazolin-5-amine (CGS-15943; 1 microM) reduced the isoproterenol-elicited contractile response of mature but not immature hearts during normal perfusion. These results suggest that myocardial adenosine modulates the beta-adrenergic-elicited contractile response of the adult heart via activation of both A1 and A2 adenosine receptors and that these functions of adenosine become expressed with myocardial maturation.
已知心肌对β-肾上腺素能刺激的收缩反应性会随着成熟或衰老而降低。本研究旨在确定抗肾上腺素能A1和刺激性A2腺苷受体在调节幼年(约25天)和成年(约79天)成熟阶段心脏β-肾上腺素能引发的收缩性能中的作用。β-肾上腺素能激动剂异丙肾上腺素,浓度为10^(-7) M时,以左心室压力最大上升速率(+dP/dtmax)评估,未成熟心脏的收缩力最大增加幅度(分别为104%和80%)大于成熟心脏,但成熟心脏静脉腺苷浓度的增加幅度(分别为738和277 nM)大于未成熟心脏。浓度为10^(-9)至10^(-8) M的异丙肾上腺素,在有无A1腺苷受体拮抗剂黄嘌呤胺同类物(XAC;0.5 microM)的情况下,对未成熟和成熟心脏的收缩力增加作用相似。此外,在冠状动脉血流量减少50%诱导的低灌注期间,XAC并未改变未成熟心脏中异丙肾上腺素引发的收缩反应。然而,在成熟心脏中,10^(-8) M异丙肾上腺素在低灌注期间,存在XAC时(79%)比不存在XAC时(60%)引发的+dP/dtmax增加幅度显著更大。在未成熟和成熟心脏中,低灌注分别使异丙肾上腺素引发的静脉腺苷浓度增加了相似幅度的76%和72%。在进一步的研究中,A2腺苷受体拮抗剂9-氯-2-(2-呋喃基)[1,2,4]-三唑并[1,5-c]喹唑啉-5-胺(CGS-15943;1 microM)在正常灌注期间降低了成熟但未降低未成熟心脏中异丙肾上腺素引发的收缩反应。这些结果表明,心肌腺苷通过激活A1和A2腺苷受体来调节成年心脏中β-肾上腺素能引发的收缩反应,并且腺苷的这些功能随着心肌成熟而表达。